Evidence map›Paper›PMID 34965962›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2022

The Immunomodulatory Enzyme IDO2 Mediates Autoimmune Arthritis through a Nonenzymatic Mechanism.

Lauren M F Merlo, Weidan Peng, James B DuHadaway, James D Montgomery, George C Prendergast, Alexander J Muller, Laura Mandik-Nayak

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.2field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Roles and mechanisms ofVirulence · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lauren M F MerloLankenau Institute for Medical Research, Wynnewood, PA.ORCID 0000-0002-5244-6448
Weidan PengLankenau Institute for Medical Research, Wynnewood, PA.
James B DuHadawayLankenau Institute for Medical Research, Wynnewood, PA.ORCID 0000-0001-8136-1999
James D MontgomeryLankenau Institute for Medical Research, Wynnewood, PA.
George C PrendergastLankenau Institute for Medical Research, Wynnewood, PA.
Alexander J MullerLankenau Institute for Medical Research, Wynnewood, PA.ORCID 0000-0001-7854-6933
Laura Mandik-NayakLankenau Institute for Medical Research, Wynnewood, PA; mandik-nayakl@mlhs.org.ORCID 0000-0001-9030-3467
Lankenau Institute for Medical Research · USThomas Jefferson University · US

Funding

IDO2 Targeting in Pancreatic CancerR01CA191191 · NCI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI PRENDERGAST, GEORGE C · 2015 to 2019
$2.0M
NCI NIH HHS R01 CA191191
6 · The paper itself

Abstract

IDO2 is one of two closely related tryptophan catabolizing enzymes induced under inflammatory conditions. In contrast to the immunoregulatory role defined for IDO1 in cancer models, IDO2 has a proinflammatory function in models of autoimmunity and contact hypersensitivity. In humans, two common single-nucleotide polymorphisms have been identified that severely impair IDO2 enzymatic function, such that <25% of individuals express IDO2 with full catalytic potential. This, together with IDO2's relatively weak enzymatic activity, suggests that IDO2 may have a role outside of its function in tryptophan catabolism. To determine whether the enzymatic activity of IDO2 is required for its proinflammatory function, we used newly generated catalytically inactive IDO2 knock-in mice together with established models of contact hypersensitivity and autoimmune arthritis. Contact hypersensitivity was attenuated in catalytically inactive IDO2 knock-in mice. In contrast, induction of autoimmune arthritis was unaffected by the absence of IDO2 enzymatic activity. In pursuing this nonenzymatic IDO2 function, we identified GAPDH, Runx1, RANbp10, and Mgea5 as IDO2-binding proteins that do not interact with IDO1, implicating them as potential mediators of IDO2-specific function. Taken together, our findings identify a novel function for IDO2, independent of its tryptophan catabolizing activity, and suggest that this nonenzymatic function could involve multiple signaling pathways. These data show that the enzymatic activity of IDO2 is required only for some inflammatory immune responses and provide, to our knowledge, the first evidence of a nonenzymatic role for IDO2 in mediating autoimmune disease.

Indexed as

AnimalsAntigens, NeoplasmArthritisAutoimmunityCell LineCore Binding Factor Alpha 2 SubunitGene Knock-In TechniquesGlyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating)Guanine Nucleotide Exchange FactorsHEK293 CellsHumansIndoleamine-Pyrrole 2,3,-DioxygenaseInflammationMiceMice, Inbred BALB CMice, Inbred C57BLAntigens, NeoplasmCore Binding Factor Alpha 2 SubunitGlyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating)Guanine Nucleotide Exchange FactorsIDO2 protein, mouseIndoleamine-Pyrrole 2,3,-DioxygenaseMicrotubule-Associated ProteinsRanBP10 protein, mouseRunx1 protein, mouse

Identifiers

PMID34965962
PMCPMC8770583
OpenAlexW4200275643

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.